 Christine Fisher
Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 15 | 2025 | 267 | 4.240 |
Why?
| | Brachytherapy | 13 | 2023 | 134 | 3.870 |
Why?
| | Endometrial Neoplasms | 10 | 2025 | 208 | 1.920 |
Why?
| | Uterine Neoplasms | 6 | 2025 | 96 | 1.690 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 7 | 2024 | 149 | 1.650 |
Why?
| | Hysterectomy | 5 | 2019 | 137 | 1.600 |
Why?
| | Breast Neoplasms | 20 | 2024 | 2452 | 1.550 |
Why?
| | Radiosurgery | 5 | 2025 | 400 | 1.440 |
Why?
| | Carcinosarcoma | 3 | 2023 | 23 | 1.290 |
Why?
| | Neoplasm Recurrence, Local | 12 | 2026 | 1137 | 1.000 |
Why?
| | Neoplasm Staging | 20 | 2026 | 1462 | 0.970 |
Why?
| | Genital Neoplasms, Female | 4 | 2024 | 99 | 0.960 |
Why?
| | Radiation Oncology | 5 | 2022 | 88 | 0.940 |
Why?
| | Databases, Factual | 5 | 2021 | 1486 | 0.930 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2024 | 141 | 0.820 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 61 | 0.740 |
Why?
| | Chemoradiotherapy | 4 | 2019 | 237 | 0.720 |
Why?
| | Radiotherapy, Adjuvant | 6 | 2019 | 222 | 0.650 |
Why?
| | Healthcare Disparities | 2 | 2018 | 727 | 0.640 |
Why?
| | Medical Oncology | 7 | 2026 | 332 | 0.600 |
Why?
| | Simulation Training | 1 | 2021 | 134 | 0.600 |
Why?
| | Female | 60 | 2026 | 78271 | 0.590 |
Why?
| | Ovarian Neoplasms | 1 | 2025 | 586 | 0.590 |
Why?
| | Margins of Excision | 1 | 2019 | 51 | 0.570 |
Why?
| | Aquaporin 4 | 1 | 2019 | 98 | 0.560 |
Why?
| | Insurance, Health | 2 | 2018 | 302 | 0.550 |
Why?
| | Necrosis | 1 | 2019 | 244 | 0.550 |
Why?
| | Aged | 26 | 2025 | 25913 | 0.490 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 199 | 0.490 |
Why?
| | Insurance Coverage | 1 | 2018 | 239 | 0.480 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 35 | 0.480 |
Why?
| | Middle Aged | 30 | 2025 | 35875 | 0.470 |
Why?
| | Standard of Care | 1 | 2016 | 80 | 0.470 |
Why?
| | Humans | 67 | 2026 | 144759 | 0.460 |
Why?
| | Perioperative Care | 1 | 2018 | 231 | 0.460 |
Why?
| | SEER Program | 6 | 2021 | 224 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1953 | 0.450 |
Why?
| | Adenocarcinoma | 4 | 2024 | 928 | 0.420 |
Why?
| | Health Plan Implementation | 1 | 2015 | 136 | 0.420 |
Why?
| | Medical Errors | 1 | 2015 | 118 | 0.420 |
Why?
| | Survival Rate | 7 | 2019 | 2089 | 0.420 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2014 | 88 | 0.410 |
Why?
| | Radiotherapy Dosage | 5 | 2023 | 289 | 0.400 |
Why?
| | Neoplasms | 3 | 2022 | 2875 | 0.400 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 340 | 0.390 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 529 | 0.390 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1455 | 0.380 |
Why?
| | Carcinoma | 1 | 2014 | 228 | 0.380 |
Why?
| | Pelvis | 1 | 2013 | 124 | 0.370 |
Why?
| | Combined Modality Therapy | 6 | 2020 | 1266 | 0.360 |
Why?
| | Prostatectomy | 1 | 2012 | 93 | 0.360 |
Why?
| | Aged, 80 and over | 13 | 2025 | 8265 | 0.350 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1356 | 0.350 |
Why?
| | Vulvar Neoplasms | 2 | 2024 | 13 | 0.340 |
Why?
| | Adult | 22 | 2025 | 40449 | 0.330 |
Why?
| | Internship and Residency | 1 | 2021 | 1257 | 0.330 |
Why?
| | Carcinoma, Endometrioid | 2 | 2023 | 51 | 0.330 |
Why?
| | Mastectomy, Segmental | 4 | 2020 | 108 | 0.310 |
Why?
| | Mutation | 3 | 2023 | 4089 | 0.300 |
Why?
| | United States | 13 | 2022 | 15966 | 0.290 |
Why?
| | Lymphatic Metastasis | 3 | 2021 | 333 | 0.290 |
Why?
| | Re-Irradiation | 2 | 2020 | 9 | 0.290 |
Why?
| | Cancer Pain | 2 | 2018 | 36 | 0.260 |
Why?
| | Prostatic Neoplasms | 2 | 2012 | 974 | 0.250 |
Why?
| | Vaginal Neoplasms | 1 | 2026 | 19 | 0.240 |
Why?
| | Sarcoma | 2 | 2021 | 205 | 0.240 |
Why?
| | Treatment Outcome | 9 | 2023 | 11679 | 0.240 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 1143 | 0.240 |
Why?
| | Retrospective Studies | 14 | 2024 | 17066 | 0.230 |
Why?
| | Mastectomy | 3 | 2020 | 162 | 0.230 |
Why?
| | Consensus | 2 | 2024 | 488 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2021 | 421 | 0.220 |
Why?
| | Neoadjuvant Therapy | 2 | 2018 | 462 | 0.210 |
Why?
| | Regression Analysis | 2 | 2019 | 1003 | 0.210 |
Why?
| | Stakeholder Participation | 1 | 2025 | 84 | 0.210 |
Why?
| | Follow-Up Studies | 4 | 2018 | 5408 | 0.200 |
Why?
| | Young Adult | 8 | 2021 | 14105 | 0.200 |
Why?
| | Prognosis | 6 | 2023 | 4282 | 0.200 |
Why?
| | Papillomavirus Infections | 2 | 2019 | 345 | 0.200 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2023 | 14 | 0.190 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 323 | 0.190 |
Why?
| | Carcinoma, Renal Cell | 2 | 2015 | 234 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 4 | 2021 | 965 | 0.190 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 189 | 0.180 |
Why?
| | Hodgkin Disease | 2 | 2016 | 171 | 0.180 |
Why?
| | Hydrocephalus | 1 | 2023 | 111 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 259 | 0.180 |
Why?
| | Brain Neoplasms | 2 | 2023 | 1318 | 0.170 |
Why?
| | Mass Spectrometry | 1 | 2025 | 750 | 0.170 |
Why?
| | beta Catenin | 2 | 2023 | 252 | 0.170 |
Why?
| | Kidney Neoplasms | 2 | 2015 | 412 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 641 | 0.160 |
Why?
| | Benchmarking | 1 | 2021 | 188 | 0.160 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 48 | 0.160 |
Why?
| | Veterans | 2 | 2022 | 1603 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 549 | 0.160 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2019 | 6 | 0.160 |
Why?
| | Benzodiazepines | 1 | 2021 | 167 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3863 | 0.150 |
Why?
| | Immunohistochemistry | 1 | 2023 | 1716 | 0.150 |
Why?
| | Lymph Nodes | 1 | 2021 | 502 | 0.140 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2021 | 215 | 0.140 |
Why?
| | Communication | 1 | 2025 | 965 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1560 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2024 | 851 | 0.130 |
Why?
| | Relative Biological Effectiveness | 1 | 2017 | 4 | 0.130 |
Why?
| | Pain Management | 2 | 2018 | 405 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 885 | 0.130 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1325 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 74 | 0.120 |
Why?
| | Adolescent | 5 | 2019 | 22428 | 0.120 |
Why?
| | Breast | 1 | 2017 | 158 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 99 | 0.120 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 2194 | 0.120 |
Why?
| | Logistic Models | 2 | 2018 | 2117 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 2 | 2024 | 2730 | 0.120 |
Why?
| | Radiotherapy Setup Errors | 1 | 2015 | 3 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 919 | 0.120 |
Why?
| | Propensity Score | 1 | 2018 | 367 | 0.120 |
Why?
| | Machine Learning | 1 | 2021 | 585 | 0.120 |
Why?
| | Radiation Injuries | 1 | 2017 | 151 | 0.110 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 100 | 0.110 |
Why?
| | Neoplasm Grading | 4 | 2019 | 307 | 0.110 |
Why?
| | Quality Control | 1 | 2015 | 163 | 0.110 |
Why?
| | Medically Uninsured | 1 | 2015 | 129 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 226 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 939 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2015 | 103 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 779 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 1059 | 0.110 |
Why?
| | Checklist | 1 | 2015 | 107 | 0.110 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 127 | 0.100 |
Why?
| | Cancer Vaccines | 2 | 2005 | 160 | 0.100 |
Why?
| | Risk Factors | 6 | 2020 | 10779 | 0.100 |
Why?
| | Breast Neoplasms, Male | 1 | 2013 | 29 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2019 | 3604 | 0.100 |
Why?
| | Skin Neoplasms | 2 | 2024 | 847 | 0.100 |
Why?
| | Internet | 1 | 2018 | 699 | 0.100 |
Why?
| | Clinical Competence | 1 | 2021 | 1244 | 0.100 |
Why?
| | Tumor Burden | 1 | 2014 | 319 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1782 | 0.100 |
Why?
| | Quality of Life | 1 | 2025 | 3185 | 0.090 |
Why?
| | Bone Neoplasms | 1 | 2015 | 253 | 0.090 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 508 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2017 | 589 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1326 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1720 | 0.090 |
Why?
| | Biomarkers, Tumor | 4 | 2023 | 1313 | 0.090 |
Why?
| | Patient Safety | 1 | 2015 | 347 | 0.090 |
Why?
| | DNA Polymerase II | 2 | 2023 | 35 | 0.090 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 36 | 0.090 |
Why?
| | Peptide Fragments | 2 | 2005 | 699 | 0.090 |
Why?
| | Medicaid | 1 | 2015 | 461 | 0.090 |
Why?
| | Texas | 1 | 2012 | 278 | 0.090 |
Why?
| | Male | 12 | 2024 | 72315 | 0.080 |
Why?
| | Disease Management | 1 | 2014 | 645 | 0.080 |
Why?
| | Age Factors | 1 | 2017 | 3333 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2637 | 0.080 |
Why?
| | Quality Indicators, Health Care | 2 | 2022 | 335 | 0.080 |
Why?
| | Registries | 1 | 2018 | 2385 | 0.070 |
Why?
| | Cohort Studies | 3 | 2021 | 5960 | 0.070 |
Why?
| | Melanoma | 1 | 2015 | 761 | 0.070 |
Why?
| | Survival Analysis | 1 | 2012 | 1382 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2015 | 780 | 0.070 |
Why?
| | Risk Assessment | 2 | 2020 | 3671 | 0.070 |
Why?
| | Fertility Preservation | 2 | 2019 | 53 | 0.060 |
Why?
| | Epidemics | 2 | 2018 | 98 | 0.060 |
Why?
| | Opioid-Related Disorders | 3 | 2021 | 600 | 0.060 |
Why?
| | Gynecology | 2 | 2018 | 178 | 0.060 |
Why?
| | Medicare | 2 | 2021 | 886 | 0.060 |
Why?
| | Prospective Studies | 4 | 2023 | 7990 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2834 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2005 | 161 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 161 | 0.050 |
Why?
| | Paget Disease, Extramammary | 1 | 2024 | 4 | 0.050 |
Why?
| | Radiotherapy | 2 | 2015 | 206 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 52 | 0.050 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 38 | 0.050 |
Why?
| | Aromatase | 1 | 2023 | 32 | 0.050 |
Why?
| | Needles | 1 | 2023 | 62 | 0.050 |
Why?
| | Time Factors | 4 | 2020 | 7173 | 0.040 |
Why?
| | Focus Groups | 1 | 2025 | 573 | 0.040 |
Why?
| | Receptors, Estrogen | 2 | 2016 | 457 | 0.040 |
Why?
| | Anthracyclines | 1 | 2021 | 47 | 0.040 |
Why?
| | Taxoids | 1 | 2021 | 116 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 52 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 457 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 176 | 0.040 |
Why?
| | Trastuzumab | 1 | 2021 | 118 | 0.040 |
Why?
| | Estrogens | 1 | 2023 | 380 | 0.040 |
Why?
| | Quinolines | 1 | 2021 | 193 | 0.040 |
Why?
| | Radiometry | 1 | 2019 | 56 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 54 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 44 | 0.040 |
Why?
| | Papanicolaou Test | 1 | 2019 | 35 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 38 | 0.040 |
Why?
| | Cervix Uteri | 1 | 2019 | 50 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 39 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2020 | 267 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2019 | 115 | 0.030 |
Why?
| | India | 1 | 2018 | 218 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 688 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 164 | 0.030 |
Why?
| | Equipment Design | 1 | 2019 | 530 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2022 | 768 | 0.030 |
Why?
| | Vagina | 1 | 2019 | 201 | 0.030 |
Why?
| | Organs at Risk | 1 | 2017 | 37 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 427 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2115 | 0.030 |
Why?
| | Skin Ulcer | 1 | 2015 | 14 | 0.030 |
Why?
| | HLA-A2 Antigen | 2 | 2005 | 35 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 39 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 47 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 985 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 548 | 0.030 |
Why?
| | Societies, Medical | 1 | 2019 | 887 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1075 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 732 | 0.030 |
Why?
| | Reoperation | 1 | 2017 | 630 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 359 | 0.020 |
Why?
| | Disease Progression | 2 | 2015 | 2847 | 0.020 |
Why?
| | Biopsy | 1 | 2017 | 1075 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2013 | 333 | 0.020 |
Why?
| | Age Distribution | 1 | 2013 | 403 | 0.020 |
Why?
| | Sex Distribution | 1 | 2013 | 386 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1166 | 0.020 |
Why?
| | Skin | 1 | 2017 | 755 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1658 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1053 | 0.020 |
Why?
| | Vinblastine | 1 | 2011 | 75 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 356 | 0.020 |
Why?
| | Dacarbazine | 1 | 2011 | 100 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1306 | 0.020 |
Why?
| | Remission Induction | 1 | 2011 | 307 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 6048 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4564 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1347 | 0.020 |
Why?
| | Bleomycin | 1 | 2011 | 253 | 0.020 |
Why?
| | Doxorubicin | 1 | 2011 | 397 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1837 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2112 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2363 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2879 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7190 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 37 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2005 | 223 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2005 | 177 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5868 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2005 | 132 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2005 | 573 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2005 | 784 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2005 | 917 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3540 | 0.010 |
Why?
| | Child | 1 | 2013 | 22633 | 0.010 |
Why?
|
|
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|